Clobazam Transdermal Patch Bypasses First-Pass Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral administration of clobazam for treating epilepsy and anxiety is associated with gastrointestinal side effects, low bioavailability, and poor patient compliance due to first-pass liver metabolism, leading to variable plasma levels and difficulties in administration, especially in children.
Innovation Solution
A transdermal drug delivery system (TDDS) that uses a reservoir or matrix patch to deliver clobazam through the skin, avoiding first-pass metabolism and providing a constant therapeutic plasma level for up to 7 days, utilizing a formulation with clobazam dissolved or suspended in a polymer matrix with permeation enhancers to improve bioavailability and patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If clobazam is administered orally, then the drug can be delivered to treat epilepsy and anxiety, but first-pass liver metabolism occurs causing low bioavailability and gastrointestinal side effects
Solution Approach 1:
The patent introduces the skin as an intermediary delivery route instead of oral administration. The transdermal patch uses permeation enhancers as mediators to facilitate drug passage through the skin barrier, avoiding the gastrointestinal tract and liver first-pass metabolism entirely. This changes the administration pathway from oral to transdermal, eliminating the harmful metabolic effects.
Solution Approach 2:
The patent changes the administration parameter from oral to transdermal delivery. By modifying the route of administration and using specific formulation parameters (permeation enhancers, controlled release matrix), the drug bypasses first-pass metabolism and achieves more reliable bioavailability without gastrointestinal side effects.
2Reliability
If oral clobazam is administered multiple times daily to maintain therapeutic plasma levels, then seizure control is improved, but patient compliance deteriorates due to frequent dosing and stigmatization
Solution Approach 1:
The transdermal patch provides continuous drug delivery over extended periods (multiple days), maintaining steady therapeutic plasma levels without interruption. This continuous action eliminates the need for multiple daily dosing, thereby improving patient compliance while ensuring reliable seizure control.
Solution Approach 2:
The patch delivers a controlled amount of drug continuously, which may be slightly more than traditional intermittent dosing during certain periods, ensuring therapeutic levels are maintained without requiring patient intervention. This excessive or continuous action compensates for the long duration between applications.
3Ease of operation
If oral clobazam is crushed for easier administration to children, then dosing ease is improved, but aspiration or choking risk increases
Solution Approach 1:
The transdermal patch serves as an intermediary delivery system that eliminates the need for oral administration entirely. For children, the patch can be applied to the skin without requiring crushing or chewing, thus maintaining ease of administration while completely avoiding aspiration or choking risks associated with crushed tablets.
4Reliability
If oral clobazam is taken during school hours or social activities, then continuous therapeutic coverage is maintained, but psychological behavior deteriorates due to stigmatization
Solution Approach 1:
The patent transitions from oral administration (requiring ingestion during daily activities) to transdermal administration (applied once and worn continuously). This dimensional change in delivery method allows therapeutic coverage to be maintained without requiring the child to take medication during school or social activities, thereby eliminating stigmatization while preserving continuous therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TDDS achieves stable plasma concentrations of clobazam, reducing gastrointestinal side effects and improving patient compliance by maintaining therapeutic levels with less frequent dosing, while minimizing gastrointestinal intolerance and enhancing bioavailability through transdermal delivery.
Implementation Method 1
utilizing a formulation with clobazam dissolved or suspended in a polymer matrix with permeation enhancers to improve bioavailability
Implementation Method 2
A transdermal drug delivery system (TDDS) that uses a reservoir or matrix patch to deliver clobazam through the skin, providing a constant therapeutic plasma level
Data Source
AI summary
A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster type for administrating clobazam for the treatment of various types of anxiety and epilepsy, for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7-day continuous application.